Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Breast 2Gynecologic 1

Conditions

Ovarian Neoplasms 7Neoplasms 4Endometrial Neoplasms 4Breast Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Lung Neoplasms 2Hematologic Neoplasms 2Colorectal Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Skin Neoplasms 1Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Rectal Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Melanoma 1Lymphoma 1Liver Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 3pembrolizumab 2amminedichloro(2-methylpyridine)platinum(II) 2Nivolumab 2Cytoreduction Surgical Procedures 2trastuzumab deruxtecan 1trametinib 1sodium thiosulfate 1pertuzumab 1pazopanib 1osimertinib 1motexafin gadolinium 1fludarabine 1danvatirsen 1dabrafenib 1cobimetinib 1cemiplimab 1alectinib 1aldesleukin 1X-Rays 1Ritonavir 1Remote Patient Monitoring 1Patient-Specific Modeling 1Pafolacianine 1Oxaliplatin 1Observation 1Mitomycin 1Microscopy, Electron 1Itraconazole 1Hyperthermic Intraperitoneal Chemotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × pertuzumab × Gynecologic × Clear all
NCT05150691 2026-01-28

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

DualityBio Inc.

Phase 1/2 Recruiting
796 enrolled
BreastGastrointestinalGynecologicThoracic

Bile Duct Neoplasms, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡